Claims

What is claimed is:

1. The use of N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine **(1)**; 1-4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one **(2)**; or a pharmaceutical acceptable salt, a pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof, in the manufacture of a medicament for treating multiple sclerosis (MS).

2. The use according to claim 1, wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).

3. The use of N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (1); 1-(5-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one (2)l or a pharmaceutically acceptable salt, a pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof, in the manufacture of a medicament to prevent multiple sclerosis (MS).

4. The use according to claim 3, wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).